These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

369 related items for PubMed ID: 20623991

  • 21. Novel therapeutic options for multiple sclerosis.
    Curtin F, Hartung HP.
    Expert Rev Clin Pharmacol; 2014 Jan; 7(1):91-104. PubMed ID: 24325127
    [Abstract] [Full Text] [Related]

  • 22. Towards immunotherapeutic drugs and vaccines against multiple sclerosis.
    Katsara M, Matsoukas J, Deraos G, Apostolopoulos V.
    Acta Biochim Biophys Sin (Shanghai); 2008 Jul; 40(7):636-42. PubMed ID: 18604455
    [Abstract] [Full Text] [Related]

  • 23. Multiple sclerosis: new treatment trials and emerging therapeutic targets.
    DeAngelis T, Lublin F.
    Curr Opin Neurol; 2008 Jun; 21(3):261-71. PubMed ID: 18451708
    [Abstract] [Full Text] [Related]

  • 24. Therapeutic Application of Monoclonal Antibodies in Multiple Sclerosis.
    Orthmann-Murphy JL, Calabresi PA.
    Clin Pharmacol Ther; 2017 Jan; 101(1):52-64. PubMed ID: 27804128
    [Abstract] [Full Text] [Related]

  • 25. Disease-modifying agents for multiple sclerosis: recent advances and future prospects.
    Menge T, Weber MS, Hemmer B, Kieseier BC, von Büdingen HC, Warnke C, Zamvil SS, Boster A, Khan O, Hartung HP, Stüve O.
    Drugs; 2008 Jan; 68(17):2445-68. PubMed ID: 19016573
    [Abstract] [Full Text] [Related]

  • 26. Combination therapies for multiple sclerosis: scientific rationale, clinical trials, and clinical practice.
    Costello F, Stüve O, Weber MS, Zamvil SS, Frohman E.
    Curr Opin Neurol; 2007 Jun; 20(3):281-5. PubMed ID: 17495621
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Emerging multiple sclerosis disease-modifying therapies.
    Giacomini PS, Darlington PJ, Bar-Or A.
    Curr Opin Neurol; 2009 Jun; 22(3):226-32. PubMed ID: 19434781
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Alternatives to current disease-modifying treatment in MS: what do we need and what can we expect in the future?
    Kappos L, Kuhle J, Gass A, Achtnichts L, Radue EW.
    J Neurol; 2004 Sep; 251 Suppl 5():v57-v64. PubMed ID: 15549357
    [Abstract] [Full Text] [Related]

  • 36. Antigen-specific therapies in multiple sclerosis.
    Sospedra M, Martin R.
    Int Rev Immunol; 2005 Sep; 24(5-6):393-413. PubMed ID: 16318988
    [Abstract] [Full Text] [Related]

  • 37. Multiple sclerosis therapies: molecular mechanisms and future.
    Fontoura P, Garren H.
    Results Probl Cell Differ; 2010 Sep; 51():259-85. PubMed ID: 20838962
    [Abstract] [Full Text] [Related]

  • 38. [Current treatment of multiple sclerosis].
    Csépány T.
    Lege Artis Med; 2011 Feb; 21(2):97-104. PubMed ID: 21710707
    [Abstract] [Full Text] [Related]

  • 39. [Multiple sclerosis, the therapeutic arsenal of today and tomorrow].
    Zéphir H.
    Soins; 2009 Nov; (740):39-41. PubMed ID: 20014532
    [No Abstract] [Full Text] [Related]

  • 40. [Multiple sclerosis: potential therapeutic options and update of ongoing studies].
    Wiendl H, Lehmann HC, Hohlfeld R, Hartung HP, Kieseier BC.
    Nervenarzt; 2004 Jun; 75(6):536-52. PubMed ID: 15257377
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 19.